Skip to main content
Publications
Melgar M, Abrams JY, Godfred-Cato S, Shah AB, Garg A, Strunk A, Narasimhan M, Koptyev J, Norden A, Musheyev D, Rashid F, Tannenbaum R, Estrada-Y-Martin RM, Patel B, Karanth S, Achenbach CJ, Hall GT, Hockney SM, Caputo M, Abbo LM, Beauchamps L, Morris SB, Cifuentes RO, de St Maurice A, Bell DS, Prabaker KK, Sanz Vidorreta FJ, Bryant E, Cohen DK, Mohan R, Libby CP, SooHoo S, Domingo TJ, Campbell AP, Belay ED. A multicenter retrospective cohort study to characterize patients hospitalized with MIS-A and COVID-19 in the United States, 2020-2021. Clin Infect Dis. 2023 Nov 17;77(10):1395-405. doi: 10.1093/cid/ciad374
Strober B, Sigurgeirsson B, Popp G, Sinclair R, Krell J, Stonkus S, Septe M, Elewski BE, Gottlieb AB, Zhao Y, Herrera V, Mordin M, Odom D, Papavassilis C, Nyirady J, Lebwohl M. Secukinumab provides clearer skin and better control on patient-reported psoriasis symptoms of itching, pain, and scaling than placebo and etanercept. J Psoriasis and Psoriatic Arthritis. 2016;1(4):167-75.